These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 32128760

  • 1. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites.
    Turner RM, Fontana V, Zhang JE, Carr D, Yin P, FitzGerald R, Morris AP, Pirmohamed M.
    Clin Pharmacol Ther; 2020 Aug; 108(2):287-297. PubMed ID: 32128760
    [Abstract] [Full Text] [Related]

  • 2. Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
    Mykkänen AJH, Tarkiainen EK, Taskinen S, Neuvonen M, Paile-Hyvärinen M, Lilius TO, Tapaninen T, Klein K, Schwab M, Backman JT, Tornio A, Niemi M.
    Clin Pharmacol Ther; 2024 Jun; 115(6):1428-1440. PubMed ID: 38493369
    [Abstract] [Full Text] [Related]

  • 3. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
    Ramakumari N, Indumathi B, Katkam SK, Kutala VK.
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
    [Abstract] [Full Text] [Related]

  • 4. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
    Hoste E, Haufroid V, Deldicque L, Balligand JL, Elens L.
    Clin Biochem; 2024 Feb; 124():110707. PubMed ID: 38182100
    [Abstract] [Full Text] [Related]

  • 5. The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
    León-Cachón RBR, Bamford AD, Meester I, Barrera-Saldaña HA, Gómez-Silva M, Bustos MFG.
    Sci Rep; 2020 Jun 01; 10(1):8900. PubMed ID: 32483134
    [Abstract] [Full Text] [Related]

  • 6. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
    Linskey DW, English JD, Perry DA, Ochs-Balcom HM, Ma C, Isackson PJ, Vladutiu GD, Luzum JA.
    Pharmacogenet Genomics; 2020 Dec 01; 30(9):208-211. PubMed ID: 32453264
    [Abstract] [Full Text] [Related]

  • 7. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
    Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A.
    Clin Pharmacol Ther; 2021 Sep 01; 110(3):733-740. PubMed ID: 34114646
    [Abstract] [Full Text] [Related]

  • 8. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
    Liu JE, Liu XY, Chen S, Zhang Y, Cai LY, Yang M, Lai WH, Ren B, Zhong SL.
    Eur J Clin Pharmacol; 2017 Nov 01; 73(11):1409-1416. PubMed ID: 28812116
    [Abstract] [Full Text] [Related]

  • 9. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
    Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, Bis JC, Brody JA, Floyd JS, Psaty BM, Molokhia M, Lapeyre-Mestre M, Conforti A, Alfirevic A, van Staa T, Pirmohamed M.
    Clin Pharmacol Ther; 2019 Dec 01; 106(6):1353-1361. PubMed ID: 31220337
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose.
    Cestari RN, Rocha A, Marques MP, de Oliveira RDR, Lanchote VL.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep 15; 1126-1127():121766. PubMed ID: 31450089
    [Abstract] [Full Text] [Related]

  • 11. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
    Dheyaa Aziz N, Abbood SH, Al-Mayali AH, Hadi NR.
    Pol Merkur Lekarski; 2023 Sep 15; 51(5):496-503. PubMed ID: 38069850
    [Abstract] [Full Text] [Related]

  • 12. Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention.
    Turner RM, Fontana V, FitzGerald R, Morris AP, Pirmohamed M.
    Br J Clin Pharmacol; 2020 Jan 15; 86(1):62-74. PubMed ID: 31656041
    [Abstract] [Full Text] [Related]

  • 13. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.
    Bakar NS, Neely D, Avery P, Brown C, Daly AK, Kamali F.
    Clin Pharmacol Ther; 2018 Jul 15; 104(1):178-187. PubMed ID: 28940218
    [Abstract] [Full Text] [Related]

  • 14. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR.
    Pharmacogenomics J; 2012 Jun 15; 12(3):233-7. PubMed ID: 21243006
    [Abstract] [Full Text] [Related]

  • 15. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people.
    Wang Y, Tian Y, Lv P, Chen L, Luo W, Jing X, Li H, Tan Z, Wang Y, Zhou H, Ouyang DS.
    Pharmazie; 2017 Jun 01; 72(6):365-368. PubMed ID: 29442027
    [Abstract] [Full Text] [Related]

  • 16. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.
    N Engl J Med; 2008 Aug 21; 359(8):789-99. PubMed ID: 18650507
    [Abstract] [Full Text] [Related]

  • 17. Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin.
    Cestari RN, de Oliveira RDR, de Souza FFL, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL.
    Clin Transl Sci; 2020 Nov 21; 13(6):1227-1235. PubMed ID: 32463566
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
    El-Zailik A, Cheung LK, Wang Y, Sherman V, Chow DS.
    J Pharm Biomed Anal; 2019 Feb 05; 164():258-267. PubMed ID: 30396053
    [Abstract] [Full Text] [Related]

  • 19. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
    Xiang Q, Chen SQ, Ma LY, Hu K, Zhang Z, Mu GY, Xie QF, Zhang XD, Cui YM.
    Pharmacogenomics J; 2018 Dec 05; 18(6):721-729. PubMed ID: 30250148
    [Abstract] [Full Text] [Related]

  • 20. Statin-associated muscle symptoms in coronary patients: design of a randomized study.
    Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E.
    Scand Cardiovasc J; 2019 Jun 05; 53(3):162-168. PubMed ID: 31030568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.